lecanemab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
lecanemab: clinical details
Prescribing considerations
- Confirm amyloid beta pathology using an approved or validated method.
- Determine ApoE4 status using a validated test, with appropriate genetic counselling and consent.
- Initiation and supervision require an experienced physician and controlled-access programme registration.
- Benefit and safety are not established in atypical, non-memory-predominant Alzheimer’s syndromes or adults with Down syndrome.
- Review cerebrovascular history, bleeding disorders and antithrombotic therapy.
Contraindications and cautions
- Hypersensitivity to lecanemab or an excipient.
- ApoE4 homozygosity is outside the licensed indication.
- Pre-treatment MRI showing prior intracerebral haemorrhage, more than four microhaemorrhages, superficial siderosis or vasogenic oedema suggestive of cerebral amyloid angiopathy.
- Ongoing anticoagulant therapy.
Monitoring
- Obtain a recent baseline brain MRI and repeat MRI at product-defined early-treatment points.
- Maintain vigilance for ARIA and arrange MRI assessment when symptoms suggest it.
- Interrupt or discontinue treatment according to symptoms and radiographic ARIA severity; permanently discontinue after a qualifying intracerebral haemorrhage.
- Observe for hypersensitivity and infusion-related reactions.
- Record the product name and batch number for biological traceability.
Clinical pharmacology
Lecanemab is a humanised IgG1 monoclonal antibody that preferentially binds toxic soluble amyloid beta protofibrils and other aggregated amyloid species. It is cleared through normal immunoglobulin proteolysis, making conventional small-molecule pharmacokinetic interactions unlikely.
Formulation and product differences
- The product is a concentrate for intravenous infusion supplied in two glass-vial fill volumes at the same concentration.
- The concentrate requires dilution in sodium chloride solution and administration through a low-protein-binding inline filter.
- Protect the solution from light; do not freeze or shake it.
lecanemab preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 100 mg/mL
lecanemab interactions
Pharmacokinetic interactions are not generally expected, but medicines affecting blood clotting need particular attention.
Anticoagulants, including warfarin and direct oral anticoagulants
Lecanemab should not be started during ongoing anticoagulant treatment because intracerebral bleeding risk may be increased.
Thrombolytic medicines
These may increase severe intracranial bleeding risk. ARIA can mimic an ischaemic stroke, so emergency clinicians must know about lecanemab treatment.
Aspirin and other antiplatelet medicines
Clinical trials found no increase in ARIA or intracerebral haemorrhage, but individual bleeding risk still requires review.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.